Abstract 4297
Background
Anxiety and distress may be experienced by cancer patients diagnosed with melanoma throughout their diagnosis and treatment. Beaumont Hospital, Dublin is a designated cancer centre and a proposal to develop an onsite melanoma patient support group (MPSG) in collaboration with the Skin Oncology CNSp, and the Cancer Nurse, Daffodil Centre, Beaumont Hospital was agreed. Aims/Objectives: To assess the interest in attending a professionally facilitated MPSG. To ascertain what type of group would benefit most. To ascertain the themes required to meet the needs of the group. To offer a supportive, safe environment for meeting and sharing experiences. To create an awareness of the support required by patients diagnosed with melanoma.
Methods
Initial planning meeting between the Skin Oncology CNS and the Cancer Nurse, resulted in an agreement to develop a MPSG. A target population was identified and the practicalities and commitment involved in co-facilitating a support group were identified. Group governance was developed. An expression of interest letter and a questionnaire was sent to the target population, specific themes were incorporated to assist development of the support group and manage its format and content.
Results
Patient responses identified a format for the support group incorporating educational and emotional support. Group rules were established and adhered to, with regular evaluation and discussion taking place allowing change to be incorporated as required. Six meetings took place in 2018/2019.
Conclusions
Future plans include: Maintain stability of the group. Continue meeting every two months. Attract new members. Review of group by questionnaire in relation to specific patient interests.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract